Introduction to traditional Chinese medicine (TCM) regulatory science for TCM high-quality development

被引:0
|
作者
Tang, Jianyuan [1 ,2 ,3 ]
Ai, Yanling [1 ]
Sun, Bo [4 ]
Hu, Jingqing [5 ]
Zhao, Junning [6 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Hosp, Chengdu 610075, Peoples R China
[2] Univ Macau, Macau Inst Translat Med & Innovat, Macau 999078, Peoples R China
[3] Tradit Chinese Med Regulating Metab Dis Key Lab S, Chengdu 610075, Peoples R China
[4] Shanghai Ctr Drug Evaluat & Inspect, Shanghai 201210, Peoples R China
[5] China Sci & Technol Dev Ctr Chinese Med, Beijing 100027, Peoples R China
[6] Natl Med Prod Adm, Natl Key Lab Drug Regulatory Sci, Beijing 100037, Peoples R China
来源
CHINESE SCIENCE BULLETIN-CHINESE | 2023年 / 68卷 / 22期
关键词
traditional Chinese medicine regulation science; drug regulation science; high-quality development; inheritance and innovation; traditional Chinese medicine regulation;
D O I
10.1360/TB-2023-0364
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In the past decade, drug regulation science has evolved into an emerging interdisciplinary discipline, which researches and develops new tools, standards and methods to evaluate drug quality, safety and efficacy. Compared with developed countries or regions, the proposal of drug regulation science in China is relatively late, and traditional Chinese medicine (TCM) regulation science lacks the same type of regulatory research and system for reference in the world. Based on the development process of drug regulation science, the frontier progress of drug regulation science in China and the United States, the European Union, Japan and other countries and regions were summarized, and the connotation and extension of Chinese medicine regulation science were comprehensively illustrated in this paper. (1) Proposal and development of drug regulation science. Since the 19th century, national governments in different countries have re-examined the positioning and function of drug regulation due to the frequent incidents of drug harm. In 2019, the National Medical Products Administration (NMPA) launched the Scientific Action Plan for Drug Regulation in China, which is the first initiation of scientific research on TCM regulation. The connotation and extension of drug regulation science have been defined by different countries or regions based on their own national conditions or circumstances, and the corresponding strategic plans have also been designed. (2) International advances in drug regulation science. To protect and promote public health in a timely manner, the U.S. Food and Drug Administration, the European Medicines Agency, and the Japan Pharmaceuticals and Medical Devices Agency have developed and issued innovative pharmaceutical countermeasures. NMPA has rated 117 key laboratories and has been successfully elected to the Management Committee of the International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use. (3) Proposal and development of TCM regulation science. In 2019, for the first time, the NMPA officially put TCM regulation into the scientific category of drug regulation. As a part of the national strategy, TCM regulatory science faces two major challenges: One is to explore the scientific nature and rationality of different regulatory models in terms of quality supervision and accessibility of TCM products; the other is to explore new tools, methods and standards for evaluation and supervision in terms of effectiveness and safety of TCM products. (4) Key tasks of TCM regulation science. Considering the national conditions, the current situation of TCM production, research, development and application and the development course of drug regulatory authorities in China, it is suggested that the scientific connotation of TCM can be studied from eight aspects: Top-level design of TCM supervision; Innovation of TCM regulatory tools; Improvement of the TCM regulatory standard system; Improvement of TCM supervision system; Strengthening the technical requirements for the supervision and control of the whole life cycle of TCM; Strengthening the intelligence construction in TCM supervision; Deepening international cooperation in the regulation of plant medicines; Cultivation of TCM supervision personnel.
引用
收藏
页码:2934 / 2942
页数:9
相关论文
共 42 条
  • [1] 对“系列方药”同步转化的创新中药研发注册路径的思考
    艾彦伶
    唐健元
    周刚
    张磊
    瞿礼萍
    黄诗尧
    杨忠奇
    元唯安
    周跃华
    王停
    赵军宁
    孙晓波
    肖小河
    杨子锋
    刘清泉
    朱明军
    冷向阳
    谢春光
    柴嵩岩
    [J]. 中国中药杂志, 2022, 47 (04) : 1120 - 1125
  • [2] Emerging technologies and their impact on regulatory science
    Anklam, Elke
    Bahl, Martin Iain
    Ball, Robert
    Beger, Richard D.
    Cohen, Jonathan
    Fitzpatrick, Suzanne
    Girard, Philippe
    Halamoda-Kenzaoui, Blanka
    Hinton, Denise
    Hirose, Akihiko
    Hoeveler, Arnd
    Honma, Masamitsu
    Hugas, Marta
    Ishida, Seichi
    Kass, George En
    Kojima, Hajime
    Krefting, Ira
    Liachenko, Serguei
    Liu, Yan
    Masters, Shane
    Marx, Uwe
    McCarthy, Timothy
    Mercer, Tim
    Patri, Anil
    Pelaez, Carmen
    Pirmohamed, Munir
    Platz, Stefan
    Ribeiro, Alexandre J. S.
    Rodricks, Joseph, V
    Rusyn, Ivan
    Salek, Reza M.
    Schoonjans, Reinhilde
    Silva, Primal
    Svendsen, Clive N.
    Sumner, Susan
    Sung, Kyung
    Tagle, Danilo
    Tong, Li
    Tong, Weida
    Van den Eijnden-van-Raaij, Janny
    Vary, Neil
    Wang, Tao
    Waterton, John
    Wang, May
    Wen, Hairuo
    Wishart, David
    Yuan, Yinyin
    Slikker, William Jr Jr
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (01) : 1 - 75
  • [3] [Anonymous], 1993, L. J F. Plan to speed approval of drugs: Makers would pay fees to U.S. Pediatrics, V92, P558
  • [4] Pharmacovigilance: An Overview
    Beninger, Paul
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (12) : 1991 - 2004
  • [5] Callreus T, 2013, PHARM MED, V27, P345, DOI DOI 10.1007/s40290-013-0039-x
  • [6] A renaissance in herbal medicine identification: From morphology to DNA
    Chen, Shilin
    Pang, Xiaohui
    Song, Jingyuan
    Shi, Linchun
    Yao, Hui
    Han, Jianping
    Leon, Christine
    [J]. BIOTECHNOLOGY ADVANCES, 2014, 32 (07) : 1237 - 1244
  • [7] China Society for Drug Regulation, 2022, CHINA FOOD DRUG ADM, V10, P4
  • [8] SEVEN TECHNOLOGIES TO WATCH IN 2023
    Eisenstein, Michael
    [J]. NATURE, 2023, 613 (7945) : 794 - 797
  • [9] Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
    Feinberg, Bruce A.
    Gajra, Ajeet
    Zettler, Marjorie E.
    Phillips, Todd D.
    Phillips, Eli G., Jr.
    Kish, Jonathan K.
    [J]. VALUE IN HEALTH, 2020, 23 (10) : 1358 - 1365
  • [10] Thalidomide
    Franks, ME
    Macpherson, GR
    Figg, WD
    [J]. LANCET, 2004, 363 (9423): : 1802 - 1811